Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
This study is ongoing, but not recruiting participants.
Study NCT00398515 Information provided by National Cancer Institute (NCI)
First Received on November 9, 2006. Last Updated on January 14, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Additional conditions recognized in this trial
Multiple Myeloma
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
flow cytometry
pharmacological study
lenalidomide
temsirolimus
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
Thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
